Objective: Sepsis remains an unresolved clinical problem. Therapeutic strategies focusing on inhibition of neutrophils (polymorphonuclear neutrophils) have failed, which indicates that a more detailed understanding of the underlying pathophysiology of sepsis is required. Polymorphonuclear neutrophil activation and chemotaxis require cellular adenosine triphosphate release via pannexin-1 channels that fuel autocrine feedback via purinergic receptors. In the current study, we examined the roles of endogenous and systemic adenosine triphosphate on polymorphonuclear neutrophil activation and host defense in sepsis. Design: Prospective randomized animal investigation and in vitro studies. Setting: Preclinical academic research laboratory.
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Dr. Li received support for article research from the National Institutes of Health (NIH). Dr. Lee received support for article research from the NIH. Dr. Ledderose received support for article research from the German Research Foundation (DFG) and the NIH. Dr. Junger received support for article research from the NIH and disclosed other support (Various types of remuneration for grant review activities from the NIH, Department of Defense, and other foreign funding agencies). His institution received funding from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. The inflammatory response to sepsis involves the activation of polymorphonuclear neutrophils (PMNs) that cause collateral damage to host organs such as the lung, liver, and kidney. In the past, we studied the activation processes that regulate PMN functions with the hope of finding novel targets that allow modulation of PMNs in critical care patients and sepsis. We found that cellular adenosine triphosphate (ATP) release via pannexin-1 (pnx1) channels and autocrine stimulation of purinergic receptors are essential steps in PMN activation (6) . ATP release and purinergic signaling regulate complex cell functions such as chemotaxis (6) (7) (8) (9) (10) (11) (12) . Chemotactic stimuli like the bacterial peptide N-formyl-met-leu-phe (fMLP) trigger ATP release from the PMN surface closest to the chemotactic source (7) . This initial ATP release stimulates P2Y2 receptors that define the leading edge and guide PMN chemotaxis. Ectonucleotidases (e.g., ectonucleotide triphosphate diphosphohydrolase-1 also known as cluster of differentiation molecule CD39) and A2a adenosine receptors also contribute to chemotaxis (8) (9) (10) . Together, P2Y2, A2a, and other purinergic receptors elicit excitatory and inhibitory responses at the front and back of cells that result in a push-pull mechanism, which guides the movement of PMNs to sites of infection (10) (11) (12) . Inhibition or genetic ablation of pnx1, P2Y2, or A2a receptors impairs chemotaxis (6, 7) . However, these endogenous purinergic signaling mechanisms of PMNs can be also impaired by external, systemic ATP that is released in response to inflammatory processes, sepsis, and host tissue damage (13) (14) (15) .
In the current study, we examined how endogenous ATP release and systemic ATP affect PMN functions in sepsis. We found that released ATP in sepsis promotes PMN activation but that it also impairs PMN chemotaxis and the ability of PMNs to locate and eliminate invading bacteria. We could show that removal of systemic ATP restores PMN chemotaxis, improves bacterial clearance, and reduces mortality in a mouse model of sepsis.
MATERIALS AND METHODS

Mouse Model of Sepsis
All animal experiments were approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center (BIDMC) and performed according to the guidelines of the National Institutes of Health. C57BL/6 wild-type (WT) mice were obtained from Charles River Laboratories (Wilmington, MA); pnx1 knockout (pnx1 KO) mice were from The Knockout Mouse Project Center for Comparative Medicine (University of California, Davis, CA) and backcrossed into the C57BL/6 background. For all experiments, male mice, 8-10 weeks old and weighing 20-25 g were used.
Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) as described previously (15) . Briefly, mice were anesthetized with isoflurane. Half of the cecum was ligated with 3-0 silk suture and punctured with a 22-G needle. Sham animals were subjected to the identical surgical procedure without CLP. Mice were resuscitated by subcutaneous injection of 1 mL of warmed 0.9% saline solution (Baxter, Deerfield, IL). Buprenorphine (0.1 mg/kg subcutaneously; Hospira, Lake Forest, IL) was administered for pain control immediately after surgery and every 12 hours until euthanasia.
Animal Treatment
Suramin (Calbiochem EMD Merck, Darmstadt, Germany) was dissolved in 0.9% saline at a concentration of 4 mM, and mice were treated by dorsal subcutaneous injection with 4 µL/g body weight (BW) of this solution (16 nmol/g) 10 minutes before or 60 or 180 minutes after CLP. Apyrase (Sigma-Aldrich Corporation, St. Louis, MO) was administered intraperitoneally at a dose of 0.6 U/g BW (6 µL/g of a 100 IU/mL apyrase solution) 30 minutes before CLP.
Bacterial Counts, WBC Counts, and Aspartate Aminotransferase (AST) Measurement Mice were anesthetized and killed by cardiac puncture, and heparinized blood was collected. Bronchoalveolar lavage fluid (BALF) was obtained by flushing the lungs twice with 1 mL ice-cold 0.9% saline. The BALF was centrifuged at 2,000 rpm for 10 minutes at 4°C and the supernatant was collected and stored at -80°C until use. Peritoneal lavage fluid was obtained by injection of 3 mL ice-cold 0.9% saline containing 1% fetal calf serum using a 26-G needle; the abdomen was gently massaged and the peritoneal fluid collected through the same needle after 5 minutes. Blood, bronchoalveolar, and peritoneal lavages were collected and spleens, livers, and lungs homogenized in 1 mL normal saline. Bacterial counts were determined as previously described (6, 7, 15) . WBC counts were determined with a hemocytometer, and AST activity in plasma was assessed with a commercially available assay kit (Biotron Diagnostics, Hemet, CA).
Survival
Animals were subjected to CLP and randomly assigned to three different treatment groups: control group (0.9% saline intraperitoneally 10 min prior to CLP), suramin group (suramin, 16 nmol/g BW subcutaneously 10 min prior to CLP), and apyrase group (apyrase, 0.6 IU/g BW intraperitoneally 30 min before CLP). Animals were monitored in 8-hour intervals. Vital signs, distress, and discomfort were scored and moribund animals sacrificed as needed. After 72 hours, all remaining mice were sacrificed.
In Vivo PMN Activation Neutrophil activation was assessed by measuring CD11b on the surface of Ly-6G positive leukocytes using flow cytometry as previously described (15) . Blood samples were subjected to RBCs lysis, washed, and incubated with allophycocyaninconjugated anti-mouse CD11b antibodies (eBioscience, Inc., San Diego, CA; 1:100) and phycoerythrin-conjugated antimouse Ly-6G antibodies (eBioscience; 1:200). Then samples were washed, fixed, and analyzed with a BD FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). For gating, isotype controls were used and only debris and platelets were excluded from analysis. In some experiments, blood samples were stimulated in vitro with 100 µM W-peptide (trp-lys-tyrmet-val-met; Tocris Bioscience, Bristol, United Kingdom) for 15 minutes at 37°C.
In Vitro PMN Chemotaxis
The Institutional Review Board of BIDMC approved all studies involving human subjects. PMNs were isolated from healthy volunteers and chemotaxis was assessed using a live cell imaging system as described previously (7). Briefly, freshly isolated PMNs plated onto 25-mm glass coverslips coated with fibronectin were placed under a microscope (Leica DMI6000B, Leica, Wetzlar, Germany) and the movement of cells in a chemoattractant gradient field generated with a micropipette loaded with 100 nM fMLP was recorded by time-lapse video microscopy (20 serial images at 20-s intervals). From these images, migration speeds and directionality of individual cells were calculated (10) .
Statistical Analysis
Data are expressed as mean ± sem (se of the mean) unless stated otherwise. Statistical analyses were done using two-tailed, unpaired Student t tests, or Mann-Whitney U test when comparing two groups, or one-way analysis of variance and Fisher post hoc least significant difference test for multiple comparisons. The survival data were analyzed by the Kaplan-Meier test. Differences between groups were considered statistically significant at p values less than 0.05. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS; IBM, Chicago, IL). Previously, we have shown that sepsis-induced ATP release in the plasma correlates with PMN activation (15) . In response to cell activation, human PMNs release ATP via pnx1 channels (6, 8) . In order to study the role of pnx1 channels in mouse PMNs, we used cells from pnx1 KO mice. In contrast to WT controls, PMNs from healthy pnx1 KO mice were unresponsive to in vitro stimulation with the mouse formyl peptide receptor agonist W-peptide (Fig. 1A) . These findings confirm previous work demonstrating that pnx1 channels deliver the ATP that fuels the autocrine purinergic signaling that is needed for PMN activation (6) . However, in response to sepsis, PMNs of pnx1 KO mice were clearly activated (Fig. 1, B-D) . Taken together, these findings indicate that pnx1 is required for the endogenous signaling mechanism that activates PMNs, but that additional pnx1-independent mechanisms also contribute to PMN activation in sepsis.
RESULTS
Pannexin Dependent and Independent Mechanisms Contribute to PMN Activation in Sepsis
Pnx1 Contributes to Bacterial Clearance in Sepsis
The findings above suggest that pnx1-independent mechanisms deliver most of the ATP that promotes PMN activation in sepsis. In WT mice with CLP, bacteria rapidly spread from the peritoneum to the peripheral blood and the lungs, suggesting inadequate host defense in sepsis ( Fig. 2A) . In order to study the role of pnx1 channels in host defense, we compared the spread of bacteria in WT and pnx1 KO mice. Mice were subjected to CLP and bacteria were counted in the blood, bronchoalveolar lavage, spleen, liver, lungs, and in the peritoneum 4 hours later. With the exception of the liver, the numbers of bacteria were significantly higher in all compartments of homozygous pnx1 KO mice compared with WT mice (Fig. 2B ). These findings demonstrate that pnx1-induced ATP release contributes to the defense against invading bacteria. The importance of pnx1 in host defense was further supported by the finding that the mortality rate was higher in pnx1 KO mice than in WT mice (Fig. 2C) . Taken together, these results indicate that pnx1 channels contribute to the host defense in sepsis.
Blocking Purinergic Signaling Reduces Host Tissue Damage but Also Impairs Host Immune Defense
The findings above demonstrate that ATP release has dual roles in sepsis, namely facilitating PMN activation that can either promote host organ damage or host immune defense. We have previously shown that inhibition of purinergic signaling with the P2 receptor antagonist suramin reduces PMN activation in sepsis (15) . Therefore, we wondered how suramin affects the protective and destructive effects of PMNs in sepsis. We tested various treatment strategies with suramin in our CLP model (Fig. 3A) . In a pilot study, we established the dose of suramin that reduced PMN activation in response to sepsis by 50%. At that dose (16 nmol/g BW), suramin had no noticeable effect on CD11b expression or AST levels in sham animals (Fig. 3,  B-D) . When administered 10 minutes prior to CLP, this suramin dose reduced PMN activation and liver damage (Fig. 3,  B-D) , but the numbers of bacteria in the peripheral blood were significantly higher than in untreated CLP mice (Fig. 3E) . These findings suggest that inhibition of PMNs with suramin at the onset of sepsis can decrease PMN activation and organ ) and homozygous (pnx1 -/-) pnx1 knockout (KO) and WT mice were subjected to CLP for 4 hr, sacrificed, and bacterial counts determined in blood, BALF, spleen, liver, lungs, and peritoneal lavage. Data shown represent the mean and sem of 3-5 mice in each group. Statistical comparisons between groups were made with analysis of variance, *p < 0.05, **p < 0.01, ***p < 0.001. C, WT mice and homozygous (pnx1 -/-) pnx1 KO mice were subjected to CLP, and survival rates were recorded for a period of 72 hr following CLP. Each group consisted of 11 animals. Survival statistics were assessed using the Kaplan-Meier test, *p < 0.05. Inhibition of P2 receptor signaling reduces host organ damage but also host immune defense in sepsis. A, Three different strategies with the aim to reduce polymorphonuclear neutrophil (PMN) activation and preserving host defense were employed, administering suramin subcutaneously at a dose of 4 μL/g body weight of a 4-mM solution either 10 min before or 1 or 3 hr after cecal ligation and puncture (CLP). B and C, Animals were sacrificed 18 hr after CLP, and PMN activation was assessed. B, This shows the percentage of activated PMNs that express the integrin CD11b on the cell surface and C, shows the abundance of CD11b on the surface of PMNs. D and E, aspartate aminotransferase (AST) levels or bacteria counts in the circulation of mice treated as described above were determined as readouts of host organ damage or host immune defense, respectively. Data shown are expressed as mean ± sem of 8-12 animals per group (analysis of variance; *p < 0.05, **p < 0.01, ***p < 0.001). CFU = colony forming units, MFI = mean fluorescence intensity.
Critical Care Medicine www.ccmjournal.org e101 damage but that this treatment also impairs the protective role of PMNs. Next, we tested whether delayed treatment with suramin would allow PMNs to mount an adequate host defense response, while still preventing subsequent PMN activation and organ damage. For that purpose, we administered suramin either 60 or 180 minutes after CLP. Delayed suramin treatment at 60 minutes was still able to reduce organ damage (Fig. 3D ) but also reduced host defense and promoted the spread of bacteria in sepsis (Fig. 3E) . Taken together, these findings suggest that blocking PMN activation in sepsis inevitably impairs the ability of PMNs to defend the host from infection.
Removal of Systemic ATP Improves Survival and Host Immune Defense in Sepsis
Our findings indicate that inhibition of PMNs with suramin reduces host organ damage but also impairs host immune defense. In order to overcome this dilemma, we tested other strategies to modulate purinergic signaling. Apyrase is an ATPase that promotes the enzymatic breakdown of extracellular ATP. We administered apyrase intraperitoneally with the goal of reducing extracellular ATP levels in the peritoneal cavity, where excessive ATP is released from damaged and inflamed tissues near the source of infection. Apyrase or suramin was administered, mice were subjected to CLP, and PMN activation, organ damage, and the spread of bacteria were assessed (Fig. 4) . Although apyrase treatment had little effect on PMN activation and organ damage (Fig. 4A) , it markedly reduced mortality (Fig. 4,  B-C) . These effects were paralleled by a significant decrease in the number of bacteria in the peritoneum and the peripheral blood (Fig. 4D) . We found that apyrase treatment diminished the concentration of extracellular ATP in peritoneal lavages, but that PMN counts in the peritoneum were unchanged (Fig. 4E ). These findings demonstrate that apyrase treatment significantly improves outcome in sepsis by promoting host immune defense and bacterial clearance.
Eliminating Systemic ATP With Apyrase Restores PMN Chemotaxis
PMNs form the first line of defense against invading bacteria. Chemotaxis allows PMNs to locate and eliminate invading bacteria. Our previous work has shown that endogenous Removing systemic adenosine triphosphate (ATP) improves host immune defense and survival in sepsis. A, Wild-type (WT) mice were randomly divided into three groups. Control mice received normal saline vehicle prior to cecal ligation and puncture (CLP); suramin was administered subcutaneously as a bolus (16 nmol/g body weight [BW]) 10 min prior to CLP; and apyrase was administered intraperitoneally as a bolus (0.6 IU/g BW) 30 min prior to CLP. Animals were sacrificed after 18 hr, and polymorphonuclear neutrophil (PMN) activation and plasma aspartate aminotransferase (AST) levels were determined. Data are expressed as percent change compared to untreated controls and represent the means ± sem of 8-12 animals per group (analysis of variance [ANOVA]; *p < 0.05, **p < 0.01, ***p < 0.001). B, Body temperature was recorded with a rectal temperature probe before surgery (t = -1 hr), at the end of surgery (t = 0 hr), and throughout the 72-hr observation period following CLP. Each data point represents the mean ± sem of six animals in each group. Differences among the three groups were analyzed with ANOVA (*p < 0.05 control vs apyrase; #p < 0.05; ##p < 0.01 apyrase vs suramin). C, Survival rates in the three treatment groups were recorded for a period of 72 hr after CLP. Each group consisted of 11 animals. Survival statistics were assessed using the Kaplan-Meier test (*p < 0.02 control vs apyrase; $p < 0.05 control vs suramin; ##p < 0.01 apyrase vs suramin). D, Numbers of bacteria in the blood and the peritoneum of mice with or without apyrase treatment were assessed 18 hr after CLP. Data are expressed as means ± sem of 17-21 animals per group (blood) and 6-10 animals per group (peritoneum). Comparisons between groups were made with ANOVA (**p < 0.005, ***p < 0.0001 control vs apyrase). E, ATP concentrations and total PMN counts in the peritoneal lavage of CLP mice without (control) and with apyrase treatment were determined (n = 3 per group). Comparisons between groups were made with ANOVA (**p < 0.005, ***p < 0.0001 control vs apyrase). CFU = colony forming units.
purinergic signaling regulates PMN chemotaxis through a delicate endogenous purinergic guidance system that directs migration to sites of infection (6) (7) (8) (9) (10) . We hypothesized that the beneficial effects of apyrase in our CLP model may be due to improved PMN chemotaxis. To test this possibility, we used a live-cell imaging system for real-time monitoring of PMN chemotaxis in a chemotactic gradient field. Freshly isolated PMNs from healthy human donors were exposed to a chemotactic gradient field generated with a micropipette loaded with the bacterial product fMLP (Fig. 5A) . Addition of ATP at concentrations similar to the systemic ATP levels found in sepsis (1-10 µM; [15] ) dose-dependently impaired chemotaxis ( Fig. 5B; Video 1 
DISCUSSION
Sepsis is accompanied by a systemic inflammatory response syndrome (SIRS) that promotes multiple organ failure and is a leading cause of death in trauma and critical care patients (1) (2) (3) (4) (5) . Most therapeutic strategies designed to treat sepsis have focused on blocking SIRS. However, virtually all clinical trials that tested this approach have yielded disappointing results and no effective treatments for sepsis are available to this day (1, 2) . These clinical findings have cast serious doubt over the feasibility of current treatment strategies and reemphasized the need for a deeper understanding of the pathophysiologic mechanisms that are involved in sepsis (16) (17) (18) . The findings of our current study support the notion that strategies aimed at blocking the inflammatory process in sepsis are not suitable to improve clinical outcome. We found that blocking of the endogenous purinergic signaling mechanisms that activate PMNs can inhibit cell activation and PMN-induced organ damage but that this approach does not improve outcome in sepsis. Instead, this approach impaired immune defenses because PMNs were no longer capable of locating and eliminating bacteria that spread throughout the host and cause fullblown sepsis. Recent work has revealed that ATP release via pnx1 and autocrine purinergic signaling regulate the activation and function of PMNs and of other immune and nonimmune cell types (12, (19) (20) (21) (22) (23) (24) . We demonstrated that these purinergic signaling mechanisms have a central role in the regulation of PMN chemotaxis (7) (8) (9) (10) (11) . However, elevated systemic ATP levels in the plasma and near the site of infection or tissue damage in critical care and trauma patients defeat the endogenous purinergic signaling mechanisms that regulate PMN chemotaxis. Stimulation of P2Y2 receptors by systemic ATP levels can enhance PMN degranulation and promote host tissue damage (6, 15, 25, 26) . However, our current findings indicate that excessive P2Y2 receptor stimulation by systemic ATP can also impair PMN chemotaxis, which is needed to protect the host from infection. Our findings suggest that systemic ATP interferes with the endogenous purinergic signaling mechanisms that regulate PMN chemotaxis. Thus, strategies that inhibit PMNs with purinergic drugs or other therapeutic agents studied in the past have two opposing effects: they reduce host organ damage but they also impair the host's immune defenses.
This dilemma is probably a major reason for the lack of progress in the development of effective therapies for sepsis. In our animal model of sepsis, we could overcome this problem with the use of apyrase that allows the removal of systemic ATP without depleting the endogenous purinergic signaling mechanisms that are required for PMN chemotaxis. Endogenous purinergic signaling that allows PMNs to determine the direction to which they must migrate in order to reach sites of infection involves P2Y2 receptors and pnx1-mediated ATP release from the cell surface closest to the source of chemoattractants (7, 8) (Supplemental  Fig. 3 , Supplemental Digital Content 4, http://links.lww. com/CCM/C86; legend, Supplemental Digital Content 5, http://links.lww.com/CCM/C87). Under normal circumstances, this purinergic signaling process results in the efficient migration of PMNs to chemotactic sources (11, 12) . The presence of systemic ATP interferes with this gradient sensing mechanisms by obscuring the endogenous ATP signal that is generated by localized ATP release and P2Y2 receptor stimulation (Supplemental Fig. 3 , Supplemental Digital Content 4, http://links.lww.com/CCM/C86; legend, Supplemental Digital Content 5, http://links.lww. com/CCM/C87). As a consequence, PMNs lose their ability to locate and kill bacteria. Removal of systemic ATP can restore PMN chemotaxis and significantly improve bacterial clearance and survival in the CLP model we used. These observations are in line with recent reports by others who demonstrated that apyrase treatment improves survival in a mouse sepsis model (27, 28) . We conclude that systemic ATP is a major culprit responsible for the pathophysiologic processes involved in sepsis. Removal of systemic ATP is a promising novel treatment strategy to treat sepsis.
